PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT04355845
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
- Conditions
- Aplastic Anemia
- Interventions
- Biological: PF-06462700
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04350606
- Locations
- 🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04351334
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT04346615
- Locations
- 🇺🇸
Jefferson Torresdale Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Abrocitinib 200 mgCombination Product: Dupilumab 300 mg
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 727
- Registration Number
- NCT04345367
- Locations
- 🇺🇸
One Health Research Clinic, Norcross, Georgia, United States
🇺🇸Paddington Testing Co, Inc., Philadelphia, Pennsylvania, United States
🇵🇱Centrum Medyczne Promed, Krakow, Poland
Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT04338204
- Locations
- 🇸🇪
Danderyds Hospital, Stockholm, Sweden
🇸🇪Gävle Hospital, Gävle, Sweden
🇸🇪SU/Sahlgrenska, Gastroenterologi & Hepatologi, Göteborg, Sweden
A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT04338711
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT04337138
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
- Conditions
- Advanced Non-squamous NSCLC
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04325698
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳Jinan Central Hospital, Jinan, Shandong, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT04323124
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium